News Briefs Archive

New Diabetic Retinopathy Tool

Sept. 7, 2016

Eyenuk has announced CE Mark and the commercial launch of EyeArt 2.0, a fully automated diabetic retinopathy screening software.

This new software tool has clinically demonstrated over 90 percent in both sensitivity and specificity, and will launch in leading eyecare centers in Europe over the next few months.

EyeArt 2.0 provides fully automated DR screening in one short office visit, including imaging, grading and reporting for DR in accordance with internationally recognized standards, such as the International Clinical Diabetic Retinopathy Disease Severity Scale (ICDR). The commercial launch is supported by a new study of the EyeArt 2.0 technology, which demonstrated 98.3 percent sensitivity in identifying potentially treatable patients with severe non-proliferative or proliferative DR, and/or the presence of surrogate markers for CSME.

In the study, the overall screening sensitivity for detecting referable DR patients was 91 percent (95 percent CI: 90.5 percent – 91.6 percent) with specificity of 90.8 percent (95 percent CI: 0.957-0.961). The study was presented on June 25 at the EASDec 2016 Meeting.

Eyenuk says EyeArt 2.0 has been tested on one of the largest data sets of patient cases of any available DR screening technology, in demanding, real-world settings using images captured in everyday practice.

The technology is designed to be flexible, and to work effectively with a variety of imaging protocols used in screening setups.

For more information, visit www.Eyenuk.com or (818) 835-3585.

To Top
Subscribe Today for Free...
And join more than 35,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.